Navigation Links
Genetics of ALS progression
Date:5/31/2008

An upcoming paper from Drs. Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) and colleagues lends new and valuable insight into the genetics of ALS.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a rapidly progressive, fatal neurological disease involving the degeneration and death of motor neuron cells.

ALS is one of the most common neuromuscular diseases worldwide, affecting as roughly 25,000 Americans, with an estimated 5,000 new diagnoses each year. The life expectancy of ALS patients is usually 3 to 5 years after diagnosis.

5-10 percent of all ALS cases are inherited. About 20% of these familial ALS cases are the result of an inherited genetic mutation on chromosome 21, in the gene encoding for the superoxide dismutase 1 (SOD1) enzyme. SOD1 is an antioxidant that protects the body from DNA damage caused by the accumulation of free radicals within cells. However, several reports have demonstrated that mutated SOD1 toxicity is not due to decreased antioxidant activity, but rather to a gain of unknown toxic function.

In their upcoming paper, Dr. Ichijo and colleagues delineate how mutations in SOD1 lead to motor neuron cell death and the progression of ALS. The researchers characterized a molecular pathway by which mutated SOD1 contributes to the accumulation of malformed proteins inside the endoplasmic reticulum (ER) compartment of motor neuron cells. Beyond a certain threshold, this ER stress induces cell death.

Interestingly, Dr. Ichijos team found that the inactivation of certain key factors in this pathway could mitigate neurodegeneration and prolong survival in a mouse model of inherited ALS.

Although not all familial ALS cases are due to the SOD1 mutation (and not all persons with a mutated form of SOD1 develop ALS), further insight into mechanism of the disease will undoubtedly aid in the development of an effective treatment for ALS.


'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related biology news :

1. Genetics determine optimal drug dose of common anticoagulant
2. American College of Medical Genetics responds to new FDA labeling decision for warfarin
3. Rutgers Genetics receives $7.8 million for autism research
4. UD leads $5.3-million research project on rice epigenetics
5. UD leads $5.3-million research project on rice epigenetics
6. Wasp genetics study suggests altruism evolved from maternal behavior
7. Maynard Olson receives $500,000 Gruber Genetics Prize
8. UBC discovery unlocks tree genetics, gives new hope for pine beetle defense
9. Ecologists, material scientists pursue genetics of diatoms elegant, etched casing
10. Scientists achieve major genetics breakthrough
11. Environmental epigenetics has potential for preventing and treating disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... , January 12, 2017 A new report by Allied Market ... the global biometric technology market is expected to generate revenue of $10.72 billion by ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and ... announced today that it will host a live webcast of its ... p.m. (ET). The webcast can be accessed from ... for replay through Tuesday, January 31, 2017. ... About BD BD is a ...
(Date:1/18/2017)... 18, 2017 Applied BioMath ( www.appliedbiomath.com ... drug research and development, today announced that Dr. ... CEO of Applied BioMath, will present at the ... (BAGIM) Meeting on Thursday January 19, 2017 at ... , MA.   Dr. Burke,s talk "Quantitative Modeling and ...
Breaking Biology Technology: